Insulet (PODD) Q2 Revenue Beats

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.50), which may not compare to the analyst estimate of $0.22. Revenue for the quarter came in at $299.4 million versus the consensus estimate of $291.45 million.

GUIDANCE:

For the year ending December 31, 2022, the Company is raising its revenue growth guidance range to 14% to 17% (previously 12% to 16%). Revenue growth ranges by product line are:

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c